Of the five approved new drugs, three are for the treatment of rare diseases. Among them, Daybue even broke the gap market and became the first therapy approved by FDA for Rett syndrome. As representatives of tumor immunotherapy, PD-1 inhibitors are also crossing over into more rare areas. Patients with Merkel cell carcinoma now have more options, and Zynyz, developed by Incyte, targeted this smaller indication to get accelerated approval from FDA, and the 5th PD-1 inhibitor in the US market was born. It is worth mentioning that Zynyz had the Greater China interest of the drug.

IQVIA predicts in its annual global drug use report that by 2027, the global drug market may increase to $ 1.9 trillion. Analysts of the Health Information Technology and Clinical Research Organization predict that the COVID-19 vaccine and therapy may increase another $ 500 billion for this. Oncology drugs are the highest-selling therapeutic agent in the world. It is expected to increase from 193 billion US dollars in 2022 to US $ 377 billion in 2027, with a compound annual growth rate of 13-16%. Immunomic drugs are the second largest treatment areas of the drug market, and it may increase to $ 177 billion by 2027. Immune agents are drugs that can change the immune response by enhancing or inhibiting the immune system. Diabetes is the third largest treatment area and will also grow at a rate of 3-6% per year. Diabetes is a chronic and life -threatening disease. There is currently no cure method. According to data from the World Health Organization, there are more than 400 million diabetic patients around the world, and their treatment accounts for about 12% of the total global medical care expenditure.